Many xenobiotics have been identified as in vitro androgen receptor (AR) antagonists, but information about their ability to produce combined effects at low concentrations is missing. Such data can reveal whether joint effects at the receptor are induced at low levels and may support the prioritisation of in vivo evaluations and provide orien tations for the grouping of anti androgens in cumulative risk assessment. Combinations of 30 AR antagonists from a wide range of sources and exposure routes (pesticides, antioxidants, parabens, UV filters, synthetic musks, bisphenol A, benzo(a)pyrene, perfluorooctane sulfonate and pentabromodiphenyl ether) were tested using a re porter gene assay (MDA kb2). Chemicals were combined at three mixture ratios, equivalent to single components' effect concentrations that inhibit the action of dihydrotesterone by 1%, 10% or 20%. Concentration addition (CA) and independent action were used to calculate additivity expectations. We observed complete suppression of dihydrotestosterone effects when chemicals were combined at individual concentrations eliciting 1%, 10% or 20% AR antagonistic effect. Due to the large number of mixture components, the combined AR antagonistic effects occurred at very low concentrations of individual mixture components. CA slightly underestimated the combined effects at all mixture ratios. In conclusion, large numbers of AR antagonists from a wide variety of sources and ex posure routes have the ability of acting together at the receptor to produce joint effects at very low concentrations. Significant mixture effects are observed when chemicals are combined at concentrations that individually do not induce observable AR antagonistic effects. Cumulative risk assessment for AR antagonists should apply grouping criteria based on effects where data are available, rather than on criteria of chemical similarity.
Introduction
Cryptorchidisms and hypospadias are the most frequent congenital malformations in boys. Although there are marked differences in regional prevalence, several countries have experienced increases in the incidence of cryptorchidisms (reviewed in: Main et al., 2010) and hypospadias (Boisen et al., 2004; Nassar et al., 2007; Nelson et al., 2005; Pierik et al., 2004) . Alcohol consumption, low birth weight, premature birth and diets lacking in protein (Pierik et al., 2004) are well recognised risk factors, but these alone cannot explain the continuing rises in inci dence. Skakkebaek et al. (2001) have proposed that cryptorchidism and hypospadias are part of the testicular dysgenesis syndrome, hypothesised to arise from insufficient androgen action in foetal life, and that exposures to anti androgenic chemicals are an etiological factor. Although evidence for links between exposure to specific chemicals and testicular dysgenesis syndrome in humans is currently limited (reviewed in: WHO, 2012) , support for the plausibility of an involvement of androgen receptor (AR) antagonists comes from experimental studies using a developmental toxicity model in the rat. In foetal life, steroidal androgens are key drivers of the differentiation of the Wolffian duct system into the vas deferens, epididymis, seminal vesicles and external genitalia. Exposure of male rats to AR antagonists and other anti androgens in foetal life leads to incomplete masculinisation and severe malformations of the reproductive organs, similar to some of the disorders seen in humans,
Methods
Test compound selection. We have previously shown that 24 current use and environmentally relevant pesticides are AR antagonists (Orton et al., 2011) , and that mixtures of these pesticides act in combination (Orton et al., 2012) . We have also shown that 17 non pesticidal pollut ants are anti androgenic and produce combination effects (Ermler et al., 2011) . In the present study, we have combined the 13 pesticides assessed earlier (Orton et al., 2011 ) with a mixture of 17 non pesticide AR antagonists (Ermler et al., 2011) . The selected chemicals are listed in Table 1 .
Chemicals. Dihydrotestosterone (DHT; N97% purity) was purchased from Steraloids Ltd. (Croydon, Surrey, UK). Dimethomorph and methiocarb were purchased from Greyhound Chromatography and Allied Chemicals (N98.7% purity; Birkenhead, Merseyside, UK). Ethyl paraben and methyl paraben were purchased from Acros Organics (N99% purity; Geel, Belgium) and hexahydrohexamethylcyclopentabenzopyran (galaxolide/HHCB), 6 acetyl 1,1,2,4,4,7 hexamethyltetraline (tonalide/ AHTN) and 2,2′,4,4′,6 pentabromodiphenyl ether (BDE100) from LGC Promochem (N 98% purity; Teddington, Middlesex, UK). 3 Benzylidene camphor (3 BC) was purchased from Induchem AG (N97% purity; Volketswil, Switzerland) and 4 methylenbenzylidene camphor (4 MBC) from Merck & Co (N 98% purity; Hertfordshire, UK). 2,2′, 3,4,4′,5′ Hexachlorobiphenyl (PCB138) was purchased from Riedel de Haen (N99% purity; Hanover, Germany). All other chemicals (N97% purity) were purchased from Sigma Aldrich (Poole, Dorset, UK). Ethanol (N 99.7% purity) was obtained from VWR International Ltd. (Leicester shire, UK). All test compounds were dissolved in ethanol to make stock solutions to be used in the assays.
MDA kb2 assay. MDA kb2 cells are a human breast cancer cell line stably transfected with an androgen responsive firefly luciferase reporter gene (American Tissue Culture Collection, ATCC, LGC standards, Teddington, UK: Wilson et al., 2002) . We have adapted and optimized the assay to meet the demands of experimental mixture studies, in terms of high reproducibility and minimal experiment to experiment variation. Details of the procedure, together with power analyses were published previously (Ermler et al., 2010) . Briefly, cells were seeded at a concentration of 1 × 10 5 cells/mL in phenol red free Leibowitz 15 me dium (Invitrogen Ltd., Paisley, UK) containing 10% (charcoal stripped) foetal calf serum (Invitrogen Ltd.) in white luminometer plates. After 28 h of treatment, luciferase activity was determined with SteadyGlo assay reagent (Promega UK Ltd., Southampton, Hampshire, UK) and measured in a plate reader (FLUOstar Optima, BMG Labtech GmbH, Offenburg, Germany) . To obtain concentration response relationships, the effects of test compounds on the luminescence produced by fixed concentrations (0.25 nM DHT) were investigated. A reduction of DHT lu minescence in concentration ranges not associated with cytotoxicity (see below) was interpreted as evidence for AR antagonism. Cells were exposed to eight serial dilutions of the selected chemicals either in the presence or the absence of DHT (0.25 nM). Concentration ranges in which the test chemicals exhibited AR antagonistic effects were established initially through screening in the range of 1.17 nM 150 μM, followed by testing of finely spaced concentrations according to the potency and toxicity of each individual mixture component.
The following controls were run on each plate: media, media with eth anol (0.25%), DHT (0.25 nM) and DHT serial dilutions (0.009 20 nM) in media with ethanol (0.25%). As positive control for an AR antagonist we used procymidone (0.005 3.2 μM) with DHT (0.25 nM) in media and ethanol (0.25%). All concentrations were tested in duplicate over two plates within each experiment, and were repeated in at least four inde pendent experimental sessions. To enable the pooling of data from dif ferent experimental sessions, luminescence readings were normalised to the readings with DHT alone (0.25 nM) and this was taken as the maximum response (100%). Solvent only (ethanol) controls were used to define the minimum response (0%), as described (Ermler et al., 2011; Orton et al., 2012) .
Cytotoxicity as a confounding factor. The MDA kb2 assay measures the decrease in luminescence induction by the DHT agonist that occurs as a result of competitive receptor antagonism. Since the luminescence signal can also be driven down by cytotoxicity, it is important to distin guish antagonism from interfering cytotoxicity. Cytotoxicity was deter mined in treatments without DHT and reductions in luminescence relative to the solvent (ethanol) controls were measured. The cytotoxic range became apparent from a down turn of the luminescence readings below the values of solvent controls (shown as insets in Fig. 1 ). Treat ments in the absence of DHT also revealed the AR agonist properties of some of the tested chemicals at higher concentrations. In these cases, cytotoxicity was evaluated in relation to the maximal AR agonistic response. This is an indirect method for determining cytotoxicity in re porter gene assays, and has been reported in the MDA kb2 assay several times previously (Ermler et al., 2011 (Ermler et al., , 2010 Korner et al., 2004; Orton et al., 2011 Orton et al., , 2012 .
Test mixtures and prediction of combination effects.
A total of 30 chemicals were combined (13 pesticides: fludioxonil, fenhexamid, ortho phenylphenol, tebuconazole, dimethomorph, imazalil, methiocarb, pirimiphos methyl, cyprodinil, pyrimethanil, vinclozolin, chlorpropham, linuron; 17 non pesticides: bisphenol A, n butyl paraben, n propyl paraben, perfluorooctane sulfonate (tetrabutylammonium salt: PFOS), 2,2′,4,4′ tetrahydroxybenzophenone (benzophenone 2), 2 hydroxy 4 methoxybenzophenone (benzophenone 3), butylated hydroxyanisole (BHA), butylated hydroxytoluol (BHT), benzo(α)pyrene (BaP), ethyl paraben, methyl paraben, galaxolide, tonalide, BDE100, 3 BC, 4 MBC and PCB138). Three mixture stock solutions with fixed mixture ratios were prepared. The mixture ratios were chosen in proportion to the concentrations of the individual mixture components that led to a sup pression of DHT effects by 1%, 10% or 20%, here termed inhibitory concen trations IC01, IC10 or IC20. Accordingly, the resulting mixtures are referred to as the IC01 mix, the IC10 mix or the IC20 mix. The composition of the mixtures is shown in Supplemental material, Table S1 . We utilised the concentration response relationships of 30 AR antagonistic chemicals (Supplemental material, Table S2 ) to predict the combined effects of three 30 component mixtures with different mixture ratios (IC01, IC10, IC20). The IC01 mixtures allowed us to assess directly whether mixture effects would arise when all components were combined at their individual IC01 concentrations. The other mixture ratios were chosen to assess whether the predictability of combination effects was affected by mixture ratio. We selected the IC20 mixture because this represents an effect mag nitude where individual components can be reliably identified as AR an tagonists because their effects are significantly different from the effects seen with cells primed with DHT in the absence of test chemicals. We have previously shown that such effect sizes are demonstrable with the experimental power afforded by the MDA kb2 assay (Ermler et al., 2010) . The IC10 mixture ratio was chosen as a value intermediate between the above two ratios. A list of regression models for the concen tration response relationships of the individual chemicals, together with estimates of their IC10 can be found in Table S2 Supplemental material. Each mixture stock solution was serially diluted and tested at least 3 times in separate experimental sessions and using new stock solu tions for each session. Two experimenters conducted the experiments separately.
The mathematical and statistical procedures used for calculating mixture effects according to concentration addition (CA) and indepen dent action (IA) follow those described in Faust et al. (2001) . Due to the mathematical features of CA, the concept cannot be used to calculate effect concentrations for the mixture that exceed the maximal AR antag onistic effect of the least efficacious compound present in the combina tion. For the mixtures investigated here, this limitation was introduced by BaP which showed AR antagonistic effects of a magnitude not exceeding 60% of the effect seen with DHT, corresponding to an inhibi tion level of 40% (θ min = 0.59, see Table 2 in Supplementary material). To construct CA prediction curves that covered the entire range of an tagonistic effects, we developed a pragmatic solution that extrapolates the toxic units (as defined in Faust et al., 2001 ) of sub maximal mixture components to effect levels beyond their maximal efficacy. In short, the contribution of BaP to the overall mixture effect was extrapolated either (i) by setting its toxic unit to zero (assuming no contribution) or (ii) by relationships became apparent with the IC10 mixture and the IC20 mixture (Table 2 ).
For the three tested mixtures, we found that the concept of IA pro duced concentration response curves with median effect concentrations 4.5 to 3 fold higher than those derived from CA. In addition, while the curves predicted by CA did not differ much for the three mixtures, the IA curves changed slightly towards lower median effect concentrations as the mixture ratio changed from IC01 to IC20 (Fig. 1) . The experimen tally observed anti androgenic effects of all three mixtures fell between the window defined by the CA and IA predictions, but came closer to the responses anticipated by CA. The closest agreement between exper iment and CA prediction was observed with the IC20 mixture where the measured effect concentrations were approximately 1.3 1.5 times larger than those predicted. In all cases, IA underestimated the experimentally observed effects by a larger margin, with predicted effect concentrations 2 4 times higher than those observed (Table 2 ).
Discussion
Our study is the first to demonstrate in vitro combination effects of mixtures containing a large number of current use AR antagonistic pesticides and a variety of other chemicals with AR antagonist properties. All the chemicals in the mixtures are relevant to human exposures typi cally experienced in industrialised countries, including the European Union and the USA (see : Ermler et al., 2011; Orton et al., 2011) . Our experiments show that large numbers of AR antagonistic chemicals can act jointly at the receptor level when present at concentrations not asso ciated with observable AR antagonism alone. Their joint AR antagonistic effects occurred at concentrations of the individual components that, if tested alone, would have produced effect magnitudes well below 1%. Such effects are too small to be measurable with the power afforded by the MDA kb2 assay (Ermler et al., 2010) . These observations are of relevance in light of realistic environmental exposure scenarios where multiple chemicals are present at low concentrations. With the excep tion of vinclozolin (e.g. Hass et al., 2007) , none of the chemicals in our mixtures have been tested in vivo for their ability to produce effects typically observed with AR antagonists, it is therefore difficult to say whether any of our selected chemicals, or their mixtures, will produce anti androgenicity in vivo. Even so, our work shows that they have the capability to elicit anti androgenic effects if they reach the AR in suffi cient quantities. Whether this is likely to happen may depend largely on toxicokinetic factors, which are currently unexplored.
Due to a lack of biomonitoring data for pollutants that occur together in human tissues, the number and composition of actual human expo sures to xenobiotics with AR antagonistic properties remains largely unknown. The risks from AR antagonists stem mostly from exposures in foetal life, and for this reason, the exposures experienced by pregnant women are of particular relevance. Two recent publications have given an impression of the combined xenobiotic exposures of pregnant women (Castorina et al., 2010; Woodruff et al., 2011) . Castorina and co authors focused on pesticide metabolites in urine, and showed that of the 34 metabolites measured, 7 were detected in over 50% of partici pants. In this study, positive correlations between some measured analytes were seen, indicating that individuals were exposed to several compounds simultaneously. Woodruff and co authors reported that the serum of individuals tested for 52 xenobiotics contained a median of 37 compounds (range: 28 45) and those tested for 71 contained a median of 50 compounds (range: 35 60). It appears therefore that co occurrence of 30 chemicals may be a quite realistic representation of the number of xenobiotics likely to be present in pregnant women in the North American population. Somewhat similar results have been reported from Europe, where 8 out of 11 phthalates/phenols in urine from Spanish pregnant women were detected in all samples (Casas et al., 2011) and UV filters, synthetic musks, parabens and phthalates were each detected in over 50% of milk samples from nursing mothers in Switzerland (Schlumpf et al., 2010) .
Our demonstrations of combination effects of diverse AR antagonists may provide a starting point for defining common assessment groups of AR antagonists in cumulative risk assessment. Ideally, such groupings should be defined on the basis of in vivo demonstrations of antiandrogenicity, but in the absence of such data, in vitro findings can give some orientation for setting priorities. Common assessment groups have traditionally been defined on the basis of mechanistic criteria and have resulted in groupings with very similar chemical structures. For example, US EPA currently conducts cumulative risk assessment for five groups of pesticides: organophosphorus compounds, N methyl carbamates, s triazines, chloroacetanilides and pyrethrins/pyrethroids (USEPA, 2006a (USEPA, , 2006b (USEPA, , 2006c (USEPA, , 2007 (USEPA, , 2011 . Although they all inhibit acetylcholinesterase, organophosphates and N methyl carbamates are not evaluated in one group, presumable because carbamylation of the enzyme by carbamates results in rapid recovery not seen with organo phosphates. A report on cumulative risk assessment for phthalates and other anti androgenic chemicals by the US National Research Council discussed the problems associated with using too narrowly focused mechanistic criteria as the basis for groupings and noted that combina tion effects arise from several phthalates together with other, structur ally diverse anti androgens, including AR antagonists (NRC, 2008) . The US National Research Council proposed a physiological grouping con cept based on common adverse outcomes and recognised that such grouping criteria go far beyond the criteria derived from similarities in chemical structures. Very recently, similar approaches have been elabo rated by the European Food Safety Authority (EFSA, 2013) . Our findings support the grouping philosophy proposed by US NRC and EFSA. Due to the features of the AR binding domain, which can accommodate a multitude of chemical structures, assessment groups for this class of agents will have to be based on common outcomes. We propose that the propensity of antagonising the AR in vitro provides a useful starting point for creating such groupings which can be refined on the basis of in vivo evidence for anti androgenicity, as and when such evidence is forthcoming.
With predictions based on the AR antagonistic effects of the individual mixture components, the concept of CA provided reasonable approxima tions of the experimentally observed combined effects, although the agreement between prediction and observation was not perfect. The observed mixture effects fell somewhat short of those anticipated by CA, nevertheless, the joint effects of all three mixture ratios were consid erably stronger than those anticipated by IA. We suggest that the slight shortfalls between the observed cumulative effects and the CA predic tions may be related to the fact that AR antagonists frequently also exhibit AR agonist properties at higher concentrations (Tamura et al., 2006) . Several of the chemicals included in the mixtures fall in that category (Ermler et al., 2011; Orton et al., 2011) and the AR agonistic effects of these mixtures overlapped with the concentration ranges where AR antagonistic effects occurred (Fig. 1, insets) . We have previously shown that when chemicals with dual AR agonist and antagonist properties are excluded from the mixtures, and only "pure" AR antagonists are com bined, perfect agreement with CA can be obtained (Orton et al., 2012) . Since the combination effect predictions are based on the AR antagonist concentration response curves of the single mixture components, the prediction concepts themselves have no facilities to directly account for AR agonism (exposure in the absence of DHT). However, agonistic effects would be indirectly accounted for under the assumption that competing agonist and antagonist effects both contribute to the antagonist concen tration response curve, provided that competition is occurring at the same target. We previously showed that when dual action antagonists are included in the mixture, observed deviation is not the result of com petition at the ligand binding domain of the AR, but rather unidentified factors cause this phenomenon (Orton et al., 2012) . Since the same pesti cides as reported in Orton et al. are included in the mixtures tested here, as well as other dual action AR antagonists (Ermler et al., 2011) , we hypothesise that similar explanations account for the observed deviation from CA.
Conclusions
We have shown that the anti androgenic effects of a mixture of AR antagonists from a wide range of sources and exposure routes are additive in this assay at very low concentrations. Since our compound selection was based on either actual or estimated human exposure in Europe and the USA, at least some of the mixture components are likely to be present simultaneously in people. Whether combined effects from exposure to AR antagonists might be produced in foetal life, thus providing a possible explanation for the rising trends in cryptorchidisms and hypospadias, will be determined by the number of AR antagonists present in tissues and their potency. However, our study has shown that the often low levels measured for individual AR antagonists are not a reliable indicator for dismissing risks from this class of chemicals. Renewed efforts of searching for AR antagonists in human tissue will be required for cumula tive risk assessment.
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